» Articles » PMID: 19406984

Human Neutrophil Peptides and Phagocytic Deficiency in Bronchiectatic Lungs

Abstract

Rationale: A well-known clinical paradox is that severe bacterial infections persist in the lungs of patients with cystic fibrosis (CF) despite the abundance of polymorphonuclear neutrophils (PMN) and the presence of a high concentration of human neutrophil peptides (HNP), both of which are expected to kill the bacteria but fail to do so. The mechanisms remain unknown.

Objectives: This study examined several possible mechanisms to understand this paradox.

Methods: PMN were isolated from sputum and blood of subjects with and without CF or non-CF bronchiectasis for phagocytic assays. HNP isolated from patients with CF were used to stimulate healthy PMN followed by phagocytic tests.

Measurements And Main Results: PMN isolated from the sputum of the bronchiectatic patients display defective phagocytosis that correlated with high concentrations of HNP in the lung. When healthy PMN were incubated with HNP, decreased phagocytic capacity was observed in association with depressed surface Fc gamma RIII, actin-filament remodeling, enhanced intracellular Ca(2+), and degranulation. Treatment of PMN with an intracellular Ca(2+) blocker or alpha1-proteinase inhibitor to attenuate the activity of HNP largely prevented the HNP-induced phagocytic deficiency. Intratracheal instillation of HNP in Pallid mice (genetically deficient in alpha1-proteinase inhibitor) resulted in a greater PMN lung infiltration and phagocytic deficiency compared with wild-type mice.

Conclusions: HNP or PMN alone exert antimicrobial ability, which was lost as a result of their interaction. These effects of HNP may help explain the clinical paradox seen in patients with inflammatory lung diseases, suggesting HNP as a novel target for clinical therapy.

Citing Articles

Alpha-defensins increase NTHi binding but not engulfment by the macrophages enhancing airway inflammation in Alpha-1 antitrypsin deficiency.

Lee J, Mohammad N, Han K, Flagg-Dowie T, Magallon M, Brantly M Front Immunol. 2025; 16:1543729.

PMID: 40013145 PMC: 11861504. DOI: 10.3389/fimmu.2025.1543729.


The Association Between Systemic Immune-Inflammation Index at Admission and Readmission in Patients with Bronchiectasis.

Gao F, He S, Li J, Wang X, Chen X, Bu X J Inflamm Res. 2024; 17:6051-6061.

PMID: 39247843 PMC: 11380867. DOI: 10.2147/JIR.S479214.


Disease Severity and Activity in Bronchiectasis: A Paradigm Shift in Bronchiectasis Management.

Im Y, Chalmers J, Choi H Tuberc Respir Dis (Seoul). 2024; 88(1):109-119.

PMID: 39218441 PMC: 11704736. DOI: 10.4046/trd.2024.0120.


Biomarkers in bronchiectasis.

Johnson E, Long M, Chalmers J Eur Respir Rev. 2024; 33(173).

PMID: 38960612 PMC: 11220624. DOI: 10.1183/16000617.0234-2023.


Basic, translational and clinical aspects of bronchiectasis in adults.

Chalmers J, Elborn S, M Greene C Eur Respir Rev. 2023; 32(168).

PMID: 37286220 PMC: 10245133. DOI: 10.1183/16000617.0015-2023.


References
1.
Panyutich A, Hiemstra P, van Wetering S, Ganz T . Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol. 1995; 12(3):351-7. DOI: 10.1165/ajrcmb.12.3.7873202. View

2.
Metzelaar M, Wijngaard P, Peters P, Sixma J, Nieuwenhuis H, Clevers H . CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem. 1991; 266(5):3239-45. View

3.
Tirouvanziam R, Gernez Y, Conrad C, Moss R, Schrijver I, Dunn C . Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc Natl Acad Sci U S A. 2008; 105(11):4335-9. PMC: 2393742. DOI: 10.1073/pnas.0712386105. View

4.
Middelhoven P, van Buul J, Hordijk P, Roos D . Different proteolytic mechanisms involved in Fc gamma RIIIb shedding from human neutrophils. Clin Exp Immunol. 2001; 125(1):169-75. PMC: 1906091. DOI: 10.1046/j.1365-2249.2001.01548.x. View

5.
Bals R, Weiner D, Meegalla R, Accurso F, Wilson J . Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol. 2001; 25(1):21-5. DOI: 10.1165/ajrcmb.25.1.4436. View